For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Estee Lauder (EL - Free Report) New York-based The Estee Lauder Companies Inc. is one of the world's leading manufacturers and marketers of skin care, makeup, fragrance and hair care products. The company’s products are sold through department stores, mass retailers, company-owned retail stores, hair salons and travel-related establishments.
EL is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Consumer Staples stock. EL has a Momentum Style Score of B, and shares are up 1% over the past four weeks.
Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.15 to $2.41 per share. EL also boasts an average earnings surprise of +39.1%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, EL should be on investors' short list.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Archer-Daniels-Midland Company (NYSE: ADM) breached their fiduciary duties to shareholders.
If you currently own Archer-Daniels stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Zacks.com users have recently been watching Strategy (MSTR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
July 03, 2026 11:30 ET | Source: Canadian National Railway Company
MONTREAL, July 03, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that it established a new monthly record for grain movement across its network. In June, CN moved 2.67 million metric tonnes (MMT) of grain from Western Canada, surpassing the previous June record of 2.64 MMT set in June 2020.
This record performance reflects continued strong customer demand, close collaboration across the grain supply chain and CN’s operational flexibility across its network. Despite heavy rainfall that affected parts of Western Canada, CN worked with customers to adjust shipping plans and move grain from available locations, maintaining strong network fluidity and efficiently moving the grain to export markets.
As the growing season continues, CN remains focused on delivering safe, consistent and reliable service for producers, grain companies and supply chain partners.
About CN
CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919.
Contacts:
MediaInvestment CommunityAshley MichnowskiJamie LockwoodSenior Manager Vice-PresidentMedia RelationsInvestor Relations and Special Projects(438) 596-4329 [email protected]
(514) 399-0052 [email protected]
Warner Bros. Discovery (WBD - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this operator of cable TV channels such as TLC and Animal Planet have returned -1.9%, compared to the Zacks S&P 500 composite's -1.7% change. During this period, the Zacks Broadcast Radio and Television industry, which Warner Bros. Discovery falls in, has lost 6%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Warner Bros. Discovery is expected to post a loss of $0.12 per share, indicating a change of -119.1% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of -$1.07 for the current fiscal year indicates a year-over-year change of -469%. This estimate has changed -14.9% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $0.03 indicates a change of +97.3% from what Warner Bros. Discovery is expected to report a year ago. Over the past month, the estimate has changed +50%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Warner Bros. Discovery is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Warner Bros. Discovery, the consensus sales estimate of $9.39 billion for the current quarter points to a year-over-year change of -4.3%. The $37.04 billion and $38.02 billion estimates for the current and next fiscal years indicate changes of -0.7% and +2.6%, respectively.
Last Reported Results and Surprise HistoryWarner Bros. Discovery reported revenues of $8.89 billion in the last reported quarter, representing a year-over-year change of -1%. EPS of -$1.17 for the same period compares with -$0.18 a year ago.
Compared to the Zacks Consensus Estimate of $8.93 billion, the reported revenues represent a surprise of -0.42%. The EPS surprise was -1070%.
Over the last four quarters, the company surpassed EPS estimates just once. The company topped consensus revenue estimates just once over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Warner Bros. Discovery is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Warner Bros. Discovery. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Key Takeaways SLB became KOC's first technology partner under the Ahmadi Innovation Valley initiative.SLB will deploy AI, IIoT, reservoir and production technologies under the seven-year agreement.SLB plans to open an innovation center in Kuwait, with operations targeted to begin in 2028. SLB N.V. (SLB - Free Report) has secured a seven-year contract from Kuwait Oil Company (KOC) under the Ahmadi Innovation Valley (AIV) initiative, strengthening its long-term growth prospects in the Middle East. The agreement makes SLB the first contracted technology partner under KOC's flagship innovation program, reinforcing the company's leadership in digital energy technologies and advanced oilfield services.
Under the contract, SLB will collaborate with KOC to develop, evaluate and deploy technologies across artificial intelligence (AI), Industrial Internet of Things (IIoT), reservoir technologies, production optimization, water management and energy transition initiatives.
The award expands a relationship spanning more than 85 years and provides SLB with a long-duration revenue opportunity while strengthening its presence in one of the world's largest oil-producing regions. Beyond technology deployment, SLB plans to establish a dedicated Ahmadi Innovation Valley facility in Kuwait, with construction beginning in 2026 and operations expected to commence in 2028. The new center will support applied research, pilot projects, technology management and knowledge transfer, creating opportunities for future service contracts and strengthening customer relationships.
The contract reflects SLB's focus on growing advanced digital and technology solutions, which generate higher profit margins than standard oilfield services. The agreement also positions the company to benefit from the growing demand for AI-enabled field optimization and automation as energy companies modernize their operations. By becoming KOC's inaugural innovation partner, SLB enhances its Middle East footprint while generating additional cash flow, strengthening its business model and increasing investor appeal.
SLB currently carries a Zacks Rank #3 (Hold).
The business models of players providing equipment and services to energy companies including SLB are dependent on capital spending by the upstream players. Therefore, Weatherford International plc (WFRD - Free Report) , which provides equipment and services to energy companies is benefiting from energy players such as Vista Energy, S.A.B. de C.V. (VIST - Free Report) and Aker BP ASA (AKRBY - Free Report) . Both these companies have upstream operations and are enjoying a favorable pricing environment, with Brent crude oil prices trading above the $70-per-barrel mark, according to oilprice.com.
WFRD, VIST and AKRBY carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Weatherford leverages its equipment and digital solutions to support oil and gas wells across 75 countries throughout their lifecycles. In the first quarter of 2026, WFRD achieved a major milestone in the U.K. sector by completing the initial deployment of its AlphaV casing system in Liverpool Bay. This historic whipstock installation in the Irish Sea lowered operational costs and delivered significant time savings for the project.
Vista operates 257,000 net acres in Argentina’s prolific Vaca Muerta basin, achieving a 67% year-over-year production growth to 134,741 barrels of oil equivalent per day (Boe/d) in the first quarter of 2026. Supported by this strong performance, VIST increased its full-year production guidance to 143,000 Boe/d.
Aker BP operates key Norwegian Continental Shelf (NCS) hubs like Alvheim, Edvard Grieg/Ivar Aasen, Valhall, Skarv and Ula, and holds a stake in Johan Sverdrup. AKRBY has strengthened its NCS portfolio by securing a 19% interest in high-potential exploration licenses, including Grosbeak, Swisher, Toppand and Rover.
Key Takeaways Ecolab closed its $4.75B CoolIT deal, adding direct liquid cooling for AI data centers.CoolIT's technology complements Ecolab's water treatment and digital monitoring capabilities.Ecolab expects High-Tech annual sales to reach $4B by 2030, with about 25% margins. Ecolab (ECL - Free Report) completed its previously announced acquisition of direct liquid cooling specialist CoolIT Systems for approximately $4.75 billion, earlier than expected. The deal significantly strengthens Ecolab's presence in the rapidly expanding AI infrastructure market by adding advanced liquid cooling technologies for high-density data centers to its portfolio.
From an investor's perspective, the acquisition marks another major step in Ecolab's strategy to transform its High-Tech business into a key long-term growth driver. By combining CoolIT's direct liquid cooling solutions with its existing water treatment and digital monitoring capabilities, Ecolab is positioning itself to capitalize on surging AI infrastructure investments while expanding its addressable market across semiconductor fabs, power generation and AI data centers.
Management expects the High-Tech business to reach $4 billion in annual sales by 2030, supporting sustained organic revenue growth, margin expansion and double-digit earnings growth over the long term despite near-term acquisition-related costs.
Likely Trend of ECL Stock Following the NewsShares of ECL have traded flat since the announcement yesterday. In the year-to-date period, shares of the company have gained 7.9% compared with the industry’s 16.1% growth. The S&P 500 increased 9.6% in the same time frame.
The CoolIT acquisition is expected to significantly strengthen Ecolab's long-term growth prospects by establishing the company as a comprehensive solutions provider across the AI infrastructure value chain. The addition of direct liquid cooling technology complements Ecolab's existing expertise in ultra-pure water, power and digital optimization solutions, enabling it to offer integrated offerings for semiconductor manufacturing and AI data centers.
As demand for high-density computing continues to rise, the acquisition should accelerate the expansion of Ecolab's High-Tech segment, deepen relationships with hyperscale customers and create cross-selling opportunities. Combined with the planned launch of its integrated 3D TRASAR cooling platform, the deal is expected to support faster revenue growth, higher operating margins and stronger recurring service revenues over the long term.
ECL currently has a market capitalization of $78.34 billion.
Image Source: Zacks Investment Research
More on the NewsFollowing the acquisition, Ecolab plans to introduce an end-to-end 3D TRASAR cooling platform at the Supercomputing conference in November 2026. The platform will combine CoolIT's cooling distribution units and high-performance cold plates with Ecolab's digital 3D TRASAR optimization technology and advanced cooling fluids. Designed for next-generation AI systems, including NVIDIA's Vera Rubin and Grace Blackwell architectures, the solution will provide real-time monitoring of cooling system performance, helping customers reduce cooling power consumption, improve energy efficiency and move toward a near-zero water footprint through closed-loop cooling technologies.
The integrated offering further expands Ecolab's capabilities across the AI infrastructure value chain, spanning ultra-pure water solutions for semiconductor manufacturing, water management for power generation and advanced liquid cooling for AI data centers.
The acquisition also significantly scales Ecolab's Global High-Tech business. Annualized sales from the segment have increased from approximately $150 million in 2021 to nearly $1.5 billion in 2026 following the acquisitions of Ovivo and CoolIT. Management now expects the business to generate $4 billion in annual sales by 2030 while delivering operating margins of about 25%, making it the company's largest growth engine. Backed by annual growth exceeding 25%, the segment is projected to contribute more than two percentage points to Ecolab's annual sales growth.
While the CoolIT acquisition is expected to create short-term earnings headwinds from non-cash amortization and financing costs, the company continues to project organic sales growth of 5-7%, annual operating margin expansion of 100-150 basis points and adjusted earnings per share (EPS) growth of 12-15% over the long term as acquisition synergies strengthen and the amortization impact from the Nalco acquisition begins to roll off after 2027.
Favorable Industry Prospect for ECLPer a report by Grand View Research, the global data center liquid cooling market size was estimated at $6.65 billion in 2025 and is projected to reach $29.46 billion by 2033, expanding at a CAGR of 20.1% from 2026 to 2033.
The rapid escalation of computing density, driven by AI, machine learning and high-performance computing workloads, is fueling the growth of the market.
A Recent Development by ECLIn April, ECL introduced Ecolab Water Navigator IQ, an AI-enabled platform that provides businesses with a comprehensive, enterprise-wide view of water performance and converts insights into actionable outcomes.
Water Navigator IQ unifies site-level data and predictive analytics in a single platform. It helps organizations track water usage, compare performance and align water strategies with business goals.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Cardinal Health (CAH - Free Report) Headquartered in Dublin, OH, Cardinal Health is one of the world’s largest healthcare services and products providers, operating across Pharmaceutical & Specialty Solutions, Global Medical Products & Distribution (GMPD), and Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, and laboratory products.The Pharmaceutical and Specialty Solutions segment distributes a wide range of pharmaceutical products, including branded and generic drugs, specialty pharmaceuticals, and consumer health products. This segment also provides biopharma solutions, offering data-driven insights, analytics, and commercialization support to pharmaceutical manufacturers. CAH delivers specialty drug distribution services in areas such as oncology, gastroenterology, and rheumatology. Its pharmacy management services cater to hospital and retail pharmacies, enhancing medication access and supply chain efficiency. The company also operates nuclear pharmacies, compounding radiopharmaceuticals used in diagnostic imaging and treatment. It currently has nearly 130 nuclear pharmacies and 30 PET cyclotron facilities.
CAH is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 19.95; value investors should take notice.
Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.20 to $10.76 per share. CAH boasts an average earnings surprise of +10.3%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, CAH should be on investors' short list.
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ZoomInfo Technologies Inc. (NASDAQ: GTM) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ZoomInfo securities between November 3, 2025 and May 11, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/GTM.
ZoomInfo Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose:
The true state of ZoomInfo's slowing seat-based demand, weakening upsell opportunities, and deteriorating fundamentals across its downmarket and upmarket segments.
That Defendants' optimistic growth narrative, including representations that full-year 2026 revenue guidance of $1.247–$1.267 billion was achievable and that Copilot penetration was on or ahead of schedule. That customers were migrating toward consumption-based models and developing internal AI-driven go-to-market solutions, trends Defendants minimized despite their material adverse impact on ZoomInfo's business.
On May 11, 2026, ZoomInfo reported its first quarter 2026 results and slashed its full-year revenue guidance by approximately $62 million
Following this news, the price of ZoomInfo's common stock declined dramatically, from a closing market price of $6.04 per share on May 11, 2026, ZoomInfo's stock price fell to $4.06 per share on May 12, 2026, a decline of about 33%.
What's Next for ZoomInfo Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/GTM. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in ZoomInfo you have until August 24, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to ZoomInfo Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for ZoomInfo Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
Key Takeaways The KOSPI index bounced back 5.76% on Friday to close at 8,088.34 after plunging to 7,300 in early morning trading SK Hynix climbed 10.88% while Samsung Electronics advanced 8.22%, erasing much of Thursday’s devastating losses News of potential collaboration between AI firm Anthropic and Samsung on custom hardware development boosted sentiment Market analysts describe Thursday’s panic selling as excessive reaction to Meta’s AI capacity monetization plans SK Hynix revealed plans for a $29.4 billion stock offering alongside an upcoming Nasdaq ADR listing to attract global investors South Korean equities mounted an impressive recovery on Friday following one of the market’s most brutal sessions in years.
The KOSPI benchmark plummeted to 7,300 during morning hours before rallying to finish 5.76% higher at 8,088.34. Trading had been suspended on Thursday after the index crashed 7.89%, triggering automatic circuit breakers.
Major Semiconductor Stocks Drive Market Rebound SK Hynix soared 10.88% on Friday, bouncing back from Thursday’s devastating 14.6% plunge. Samsung Electronics climbed 8.22%, recouping a significant portion of its 9.1% decline from the previous session.
SK hynix Inc. (000660.KS) These semiconductor giants represent the heaviest weightings in the KOSPI. Their performance heavily influences the broader index direction.
Market sentiment received additional support from emerging reports suggesting Anthropic, an artificial intelligence company, is negotiating with Samsung to co-develop specialized hardware solutions.
American memory chip manufacturer Micron experienced a 5.5% decline on Thursday, settling at $975.56. Despite the pullback, the stock maintains gains exceeding 166% year-to-date as memory semiconductors remain central to AI infrastructure investment themes.
The KOSPI has surged approximately 92% in 2026, establishing itself as the globe’s top-performing major equity index. This substantially outpaces the S&P 500’s 9.3% advance during the same timeframe.
Market Experts Label Thursday’s Panic Selling as Excessive The catalyst for Thursday’s market collapse was a report indicating Meta intends to monetize excess AI computing infrastructure. Market participants interpreted this as a signal that artificial intelligence capital expenditure had reached its zenith.
Multiple South Korean financial institutions challenged this interpretation.
Kim Joong-han, an analyst at Samsung Securities, argued that computing capacity remains in “absolute shortage” and suggested the entire sector, Meta included, continues facing capacity constraints.
Kim Young-gun from Mirae Asset Securities characterized the selloff as “a valid window for bargain buying in semiconductor stocks.”
Mirae Asset projects global technology giants will deploy $806 billion in capital expenditures this year, representing a 73% year-over-year increase. The firm anticipates spending growth exceeding 20% in the following year.
Major technology companies disclosed combined order backlogs totaling $2.1 trillion in Q1, marking a 24% quarterly increase. Approximately $656 billion of these orders are projected to convert into revenue within a two-year window.
In a separate development this week, SK Hynix’s board greenlit a substantial $29.4 billion secondary share offering in conjunction with plans to list American Depositary Receipts on the Nasdaq Global Select Market.
This strategic initiative could broaden SK Hynix’s shareholder base and enhance access to American capital markets. Analysts identify potential dilution and market absorption capacity as primary concerns surrounding such a substantial equity raise.
The market faces its next critical test on July 7, when Samsung is scheduled to publish preliminary second-quarter financial results. These figures will likely determine whether Friday’s rally proves sustainable or merely represents a temporary reprieve.
For those looking to find strong Transportation stocks, it is prudent to search for companies in the group that are outperforming their peers. Is CSX (CSX - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Transportation sector should help us answer this question.
CSX is one of 110 individual stocks in the Transportation sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CSX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CSX's full-year earnings has moved 3.1% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, CSX has moved about 34.9% on a year-to-date basis. Meanwhile, the Transportation sector has returned an average of 16.6% on a year-to-date basis. As we can see, CSX is performing better than its sector in the calendar year.
One other Transportation stock that has outperformed the sector so far this year is C.H. Robinson Worldwide (CHRW - Free Report) . The stock is up 18.1% year-to-date.
Over the past three months, C.H. Robinson Worldwide's consensus EPS estimate for the current year has increased 3.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, CSX belongs to the Transportation - Rail industry, a group that includes 9 individual stocks and currently sits at #105 in the Zacks Industry Rank. This group has gained an average of 22.4% so far this year, so CSX is performing better in this area.
C.H. Robinson Worldwide, however, belongs to the Transportation - Services industry. Currently, this 20-stock industry is ranked #156. The industry has moved +11% so far this year.
Investors with an interest in Transportation stocks should continue to track CSX and C.H. Robinson Worldwide. These stocks will be looking to continue their solid performance.
Michael Burry, the Scion Asset Management founder popularized in The Big Short, disclosed a new short position against Micron Technology (NASDAQ:MU | MU Price Prediction) in a Substack post dated July 2. Burry stated that the puts “seemed expensive,” so he shorted the stock directly and would add puts if volatility eases. He identified his disclosed entry at $1,051.87 per share.
The Micron short adds to a broader campaign. On June 30, Burry disclosed shorts against NVIDIA (NASDAQ:NVDA), Applied Materials (NASDAQ:AMAT), and the iShares Semiconductor ETF (NASDAQ:SOXX), arguing that AI-related chip stocks may be due for a 30% correction.
With the U.S. markets closed for the holiday, the disclosure lands into a market where every one of Burry’s targets has ripped higher year to date. His thesis leans on cycle history and stretched technicals.
The Micron Short: A Contrarian Call on a Cyclical Winner Micron shares are up 242% year to date (YTD) through July 2, with a market cap near $1.17 trillion. Burry argues that the rally has reached “historically extreme” levels, with Micron stock more extended above its 200-day moving average than at any point since 1984, “not even during the dot-com peak.”
Burry stated, “Micron defines cyclical like no other,” citing 34 drawdowns of more than 30% over 42 years, a median return on invested capital (ROIC) of 4%, and return on equity (ROE) of 7%, which he called “frankly terrible.” He added that “one quarter in every three, Micron is a destroyer of capital,” with free cash flow negative 48% of the time.
His view: the move reflects fear of missing out (FOMO) and greater-fool dynamics around high-bandwidth memory (HBM) being “sold out through 2026.” The timing carries some irony given President Trump praised Micron for a $250 million Trump Accounts commitment, and CEO Sanjay Mehrotra highlighted more than $200 billion in U.S. memory investment.
The bull case remains formidable. Micron posted Q3 FY26 revenue of $41.46 billion, up 346% year over year (YoY), and guided Q4 revenue to approximately $50 billion per its 8-K filing. Mehrotra stated results “reflect the strategic value of memory in the AI era.” Analysts carry an average MU stock price target of $1,486, with 30 Buy and 9 Strong Buy ratings.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
NVIDIA and Applied Materials: AI Capex Trade in the Crosshairs NVIDIA stock is up 24% over the past year to $194.83, and trades at a forward P/E ratio of 23x. NVIDIA’s Data Center revenue reached $75.25 billion last quarter, and CEO Jensen Huang asserted, “The buildout of AI factories, the largest infrastructure expansion in human history, is accelerating at extraordinary speed.” Furthermore, total supply commitments of $119 billion anchor a bet on durable AI demand for NVIDIA.
Applied Materials shares have surged 135% YTD to $603.04. CEO Gary Dickerson declared that the company “delivered record quarterly performance,” and he now expects semiconductor equipment revenue to “grow more than 30 percent in calendar 2026.” Burry’s short thesis likely ties to China exposure at 27% of total revenue and the AI capex cycle’s sustainability.
Meanwhile, the iShares Semiconductor ETF is up 86% YTD, indicating that positive assumptions about the semiconductor sector may already be priced into these stocks. Also, the prediction markets on Polymarket show only a 0.6% probability that NVIDIA closes above $260 by end of July, hinting at range-bound expectations. All in all, a sector-wide drawdown could compound the gains with Burry’s single-name shorts.
What Investors Can Watch Now Burry has been early on cyclical calls before, though short sellers face unlimited-loss risk. Shorts against structurally growing themes can bleed for extended periods before any thesis pays off.
Investors watching the debate may want to watch HBM pricing and hyperscaler capex commentary. They can also be on the lookout for Micron’s Q4 earnings report, which targets $50 billion ±$1 billion in revenue; this could either extend the AI memory thesis or expose the cyclicality that Burry highlights. Cautious position sizing on either side seems reasonable, given Micron stock’s beta of 2.17.
Burry’s disclosure could reshape sentiment among traders who track his positioning, though his thesis remains opinion rather than certainty. The next earnings cycle across the chip supply chain may determine whether his contrarian bet ages well or arrives too soon.
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Applied Materials (AMAT - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Applied Materials currently has an average brokerage recommendation (ABR) of 1.45, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 38 brokerage firms. An ABR of 1.45 approximates between Strong Buy and Buy.
Of the 38 recommendations that derive the current ABR, 28 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 73.7% and 7.9% of all recommendations.
Brokerage Recommendation Trends for AMAT
Check price target & stock forecast for Applied Materials here>>>
The ABR suggests buying Applied Materials, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Should You Invest in AMAT?Looking at the earnings estimate revisions for Applied Materials, the Zacks Consensus Estimate for the current year has increased 0.7% over the past month to $12.11.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Applied Materials. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Applied Materials may serve as a useful guide for investors.
Did you buy ZTS securities between January 14, 2025, and May 6, 2026?
Affected ZTS Investor Summary
Who: Zoetis Inc. (NYSE: ZTS)What: Securities fraud class action lawsuit filedClass Period: January 14, 2025 through May 6, 2026Deadline to Seek Lead Plaintiff Status: July 27, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company’s product adoption.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa., July 03, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Zoetis Inc. (Zoetis) (NYSE: ZTS) on behalf of those who purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”). The lawsuit is filed in the United States District Court for the Southern District of New York and is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.). Investors have until July 27, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Zoetis securities and have lost money on your investment, please provide your information here:
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
ZOETIS INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Zoetis is an animal health company that develops, manufactures, and sells vaccines, medications, diagnostics, and more for companion and livestock animals.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) prescription growth and use of Librela, a pain treatment for dogs, was weakening following FDA safety warnings of serious neurological complications; (2) Simparica Trio, a preventative for fleas, ticks, and heartworm, was losing significant market share to a lower priced competitor; (3) the company’s dermatological products, specifically Apoquel and Cytopoint, were also losing market share to competition; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Why did Zoetis’s Stock Drop?
On May 7, 2026, Zoetis reported its 2026 first quarter financial results which showed significant decline across its Companion Animal business. On this news, Zoetis’s stock price fell 21.5%.
WHAT ZTS INVESTORS CAN DO NOW:
File to be lead plaintiff by July 27, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR ZOETIS INC. INVESTORS:
Zoetis investors may, no later than July 27, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Zoetis investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Key Takeaways Elevance sued CMS over a Medicare Advantage Star Ratings change it says favored a competitor.ELV says the disputed ratings decision cost about $115 million in Medicare Advantage bonus payments.A ruling could reshape CMS' ratings process and affect insurer payments and competitive positioning. Elevance Health, Inc. (ELV - Free Report) recently filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), arguing that the agency unfairly changed the Medicare Advantage Star Ratings of one of its competitors after the ratings had already been finalized. Per reports, Elevance claims CMS gave the rival special treatment by recalculating its scores under a different standard while denying similar relief to other insurers.
The company indicates the move created an uneven competitive landscape. Through the lawsuit, Elevance is asking the court to overturn CMS' decision and restore a consistent ratings process for all Medicare Advantage insurers, according to reports.
The dispute centers on Medicare Advantage Star Ratings, which measure plan quality and directly affect bonus payments, marketing strength and member enrollment. According to the lawsuit, CMS revised a competitor's (Clover Health) ratings after identifying an error in its calculations but refused to apply the same approach across the broader industry. ELV estimates the disputed decision cost it about $115 million in Medicare Advantage quality bonus payments.
Elevance argues that once ratings are released, all insurers should be treated under the same rules instead of making company-specific adjustments. The outcome could have meaningful financial consequences for Elevance and other Medicare Advantage insurers.
Higher Star Ratings unlock quality bonus payments from CMS, improve rebate funding and make health plans more attractive during enrollment. Federal spending on Medicare Advantage quality bonuses is expected to top $13 billion this year, rising from 2025 even as the percentage of members in high-performing plans declines, per KFF.
If the court sides with Elevance, CMS could be forced to revisit its ratings process, potentially affecting payments and competitive positioning across the industry. If CMS prevails, the disputed ratings would remain in place, leaving Elevance at a competitive disadvantage against the benefited rival. The case also adds regulatory uncertainty for insurers that rely heavily on Medicare Advantage for future earnings growth.
ELV’s Price PerformanceElevance Health shares have gained 19.2% in the past year compared with the 1.4% rise of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Other Key PicksElevance Health currently has a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader Medical space are CVS Health Corporation (CVS - Free Report) , Pediatrix Medical Group, Inc. (MD - Free Report) and Biodesix, Inc. (BDSX - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for CVS Health’s 2026 bottom line suggests 10.2% year-over-year growth. CVS has witnessed 12 upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 16.8%.
The Zacks Consensus Estimate for Pediatrix Medical’s full-year 2026 earnings indicates a 9.3% year-over-year increase. MD beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 21.3%. The consensus mark for revenues suggests 1.3% growth from the year-ago period.
The Zacks Consensus Estimate for Biodesix’s 2026 full-year earnings implies a 37.7% improvement from the year-ago reported figure. BDSX beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 25.6%. The consensus mark for its current-year revenues is pegged at $110.95 million, which indicates a 25.4% year-over-year increase.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: TJX (TJX - Free Report) Based in Framingham, MA, The TJX Companies, Inc. is a leading off-price retailer of apparel and home fashions in the U.S. and worldwide. The company’s broad range of assortments at varying prices helps it to reach out to a broad range of consumers. In addition to these, The TJX Companies emphasizes a frequent flow of fresh merchandise to stores and online. As of Jan. 31, 2026, the company operated a total of over 5,214 stores across the United States, Canada, the United Kingdom, Europe and Australia.
TJX is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. TJX has a Growth Style Score of A, forecasting year-over-year earnings growth of 9.3% for the current fiscal year.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2027, while the Zacks Consensus Estimate has increased $0.11 to $5.17 per share. TJX also boasts an average earnings surprise of +8.8%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TJX should be on investors' short list.
The partnership will help farmers in Europe improve nutrient use efficiency July 03, 2026 10:00 ET | Source: Arevo
UMEÅ, July 03, 2026 (GLOBE NEWSWIRE) -- Corteva, a global pure-play agriculture company, and Arevo, a Swedish science-led crop nutrition company, have announced a partnership on Arginex Soy, Arevo’s seed applied crop nutrition system.
Corteva and Arevo Partner on Soy Crop Nutrition
Arginex Soy is an innovative arginine1-based seed treatment designed to strengthen root systems, increase nodulation and improve soybean performance, offering growers a new way to boost yields and crop resilience while advancing more sustainable production practices.
In soybeans, arginine helps stimulate the growth of root hairs, which are important for the formation of nodules where beneficial nitrogen-fixing bacteria take hold. This helps strengthen the plant’s natural ability to fix nitrogen and supports healthier root development and more efficient nutrient use from the earliest stages of growth.
Corteva is integrating the product, which is already available to farmers in Europe, into its soybean seed treatment portfolio to help get crops off to the best start.
The agreement follows a multi-stage technical evaluation assessing agronomic performance, formulation stability, and operational compatibility with Corteva’s existing soybean seed treatment portfolio.
The evaluation confirmed that Arginex Soy can deliver measurable crop performance benefits while fitting seamlessly into existing seed treatment processes, reducing barriers to adoption and enabling growers to access the technology through established commercial channels.
Leonardo Costa, EMEA Seed Applied Technologies Leader, Corteva Agriscience, said: “Rigorous evaluation has confirmed that Arginex Soy delivers the consistency and formulation stability required for Corteva’s seed applied technologies. This enables seamless integration into existing systems and provides farmers with a practical solution to support early crop establishment and improve nutrient use efficiency from the start.”
Niklas Åström, Chief Executive Officer, Arevo, said: “Being selected following this level of technical evaluation is an important milestone for Arevo. It confirms that Arginex can be integrated into established seed platforms.”
1 Arginine is an organic nitrogen source that plants absorb preferentially. Combined with phosphate, it forms a stable compound designed to remain available in the root zone over time.
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world’s most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.
Follow Corteva on Facebook, Instagram, LinkedIn and YouTube.
# # #
July 3, 2026
™ ® Trademarks of Corteva Agriscience and its affiliated companies.
About Arevo
Arevo is a Swedish science-led crop nutrition company. Its arginine-based technology, Arginex, is designed to enhance a plant’s natural ability to absorb nutrients and water, support beneficial soil microbes, and produce stronger, more resilient crops. Built commercially for agriculture, forestry and horticulture, Arevo’s mission is to reduce dependence on synthetic fertilisers and support more sustainable cultivation practices with zero nitrogen waste. Learn more at www.arevo.se.
Key Takeaways Carvana raised advertising expenses by $92 per retail unit sold in first-quarter 2026.Carvana sees advertising as a key growth pillar alongside referrals, repeat business and customer experience.CVNA says online used-car retail is still early, supporting continued broad-based marketing investment. Carvana Co. , a leading e-commerce platform for buying and selling used cars, isn't just selling more used cars—it's spending aggressively to ensure more consumers know, trust and choose its online car-buying platform.
Carvana increased its advertising expense by $92 per retail unit sold in the first quarter of 2026 as it continued investing in building customer awareness, understanding and trust in its online car-buying platform. The company currently holds nearly 2% of the U.S. used-vehicle retail market, while e-commerce adoption across other retail categories is around 20%, suggesting that online used-car retail remains in the early stages of adoption.
As Carvana scales, it expects to achieve meaningful SG&A leverage through continued operational efficiencies and greater absorption of fixed costs. Increasing awareness, understanding and trust is one of the company's three key growth pillars.
Carvana believes it is still in the early stages of telling its story to consumers and therefore sees ample opportunity to continue investing in advertising. The company expects its marketing efforts to remain broad-based across multiple channels to reach diverse customer segments. Although Carvana did not provide specific guidance on future advertising spending, its advertising expense per retail unit has remained relatively consistent over the past two to three quarters, which it considers a reasonable baseline going forward.
While Carvana is focusing on advertising to expand awareness of its online marketplace, other automotive retailers are pursuing digital strategies of their own to improve customer experience, increase efficiency and support profitability. CVNA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lithia Motors, Inc.’s digital platforms, Driveway and GreenCars, are helping boost profitability and expand its market presence. These e-commerce platforms let customers buy, sell and service vehicles online. Early results from Lithia’s investment in Wheels, a top fleet management company, are also strong. Its minority stake in Wheels creates powerful synergies between retail and fleet operations. Together, these moves strengthen Lithia’s mobility ecosystem and support customer retention and long-term profitability.
Group 1 Automotive, Inc. is steadily improving its sales process through digital tools, moving beyond just generating online leads to closing deals faster and at lower cost. Virtual finance and insurance are now available in about one-third of Group 1’s U.S. stores and handle roughly 20% of deals there, with positive customer feedback and lower compensation costs. At the same time, tools like AcceleRide, along with AI-based scheduling and CRM platforms, are helping Group 1 work more efficiently, improve deal conversions and deliver more consistent performance across its dealerships over time.
Carvana’s Price Performance, Valuation and EstimatesCarvana has underperformed the Zacks Internet – Commerce industry in the last six months. CVNA shares have plunged 20.2% compared with the industry’s decline of 4.8%.
Image Source: Zacks Investment Research
From a valuation perspective, Carvana appears overvalued. Going by its price/sales ratio, the company is trading at a forward sales multiple of 2.37, higher than its industry’s 1.99.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Carvana’s 2026 and 2027 EPS has moved up 6 cents each in the past 60 days.
The automotive industry has long been plagued with negative narratives. A primary example is that operations are capital intensive and leave automakers with thin margins, which hurts earnings potential and valuations.
But the automotive industry is evolving rapidly to include more software and technology to power automated driving features, advanced infotainment solutions, and over-the-air updates that can lower costs due to no required service center visits -- all while improving the driving experience.
These factors can fundamentally change automakers as investments, and here are two examples of how Rivian Automotive (RIVN +8.41%) and General Motors (GM +0.71%) could generate billions through unique software innovations and strategies.
First up: Rivian Toward the end of 2024, Rivian and Volkswagen partnered to develop a state-of-the-art, software-defined-vehicle (SDV) architecture that could be used across the duo's vehicle portfolios. The initial investment was significant, the potential is massive, and its financial implications are already powering Rivian. Let's dive deeper.
Today's Change
(
8.41
%) $
1.45
Current Price
$
18.63
Volkswagen's initial investment into Rivian was for up to $5 billion, which was quickly bumped to $5.8 billion and would be delivered upon completion of certain objectives and milestones. Upon the late 2024 launch, a $1.3 billion lump-sum investment was sent Rivian's way, followed by an early 2025 $1 billion tranche, a mix of equity and debt, to complete operational milestones. After passing winter testing in the spring of 2026, it unlocked another $1 billion investment from Volkswagen and also established the latter as Rivian's largest shareholder, displacing Amazon.
Investors need only glance at first-quarter 2026 results to see the impact Rivian's software is having on its financials. Consolidated revenue checked in at $1.28 billion, which was largely driven by two segments: automotive and software and services. The former generated $908 million, or a 2% decrease compared to the prior year, while software and services generated $473 million, a 49% increase.
The revenue growth was positive, but the impact on gross profit is arguably more important. The automotive segment gross profit was $62 million during Q1, while the software and services segment gross profit totaled $181 million.
The profitability boost from the software business has already powered the young electric vehicle (EV) maker to a positive gross profit result during Q1 -- superior to rival Lucid Group, which is struggling to improve gross profitability -- and giving investors reason to believe it can one day generate bottom-line profits and become a viable long-term investment.
Keep in mind there's plenty of software business growth from Rivian's partnership with Volkswagen alone, and it opens the door for other traditional automakers to explore potentially lucrative software opportunities with Rivian.
Next up: General Motors General Motors gives investors another angle in how to monetize software innovations. The Detroit automaker expects massive growth from OnStar and Super Cruise subscriptions, and it even has a long-term strategy to help drive this into reality.
Image source: General Motors.
Let's take a look at some real-world data to emphasize the software potential. Last year, GM logged $2.7 billion in realized revenue and $5.4 billion in deferred revenue from OnStar and Super Cruise subscriptions -- healthy growth from $1.7 billion realized and only $200 million deferred as recently as 2020. This business is growing quickly with management expecting those software services to generate $3.1 billion in realized revenue and $7.5 billion in deferred revenue this year.
Investors would be wise not to underestimate how this business -- with margins that could approach 70% gross margin, according to GM -- stands to change GM as an investment in an industry known for low margins. "These software-like margins that are coming in the connected business can actually drive, and potentially over time, dwarf even the wholesale business, which is remarkably strong and remarkably large," CFO Paul Jacobson said, according to Automotive News.
GM is putting its money where its mouth is, too. Beginning with the 2025 model year, every new GM vehicle that rolls off the production line includes an eight-year basic OnStar subscription, and vehicles with Super Cruise will have a three-year subscription built into the price. This is essentially opening the widest funnel top to its software and services businesses, and banks on customers getting accustomed to these, and resubscribing and/or repurchasing them with their next vehicles.
Early evidence is fairly positive. At least 30% of the 35,000 GM drivers with an expiring three-year Super Cruise subscription renewed in 2025.
Today's Change
(
0.71
%) $
0.54
Current Price
$
76.06
What it all means Automakers are quickly evolving with the industry, and vehicles are becoming packed with more software technology and innovations. This is enabling new business models to generate incremental revenue streams, as well as higher margins. Furthermore, in the long term, it could help an industry plagued with paltry price-to-earnings (P/E) multiples to rise as Wall Street acknowledges the more profitable businesses in the years ahead.
Rivian and GM aren't tech stocks, but software could certainly power their stocks higher over the next decade.
The Form 4 flow at Rivian Automotive (NASDAQ:RIVN | RIVN Price Prediction) looks ugly at a glance. The CEO sold shares, the CFO sold shares, and several other officers disposed of shares in May. Add in very bearish Reddit sentiment on 8 of 10 recent readings, and it is easy to reach for the “insiders are dumping” narrative. The filings tell a more nuanced story.
The Executive Sales Are on Autopilot Chief Financial Officer Claire McDonough’s disposals follow a textbook staircase: $18.00 on April 22, $13.4346 on May 18, $14.00 on May 21, $16.00 on May 29, and $18.00 on June 3. That price-agnostic rhythm is the hallmark of a Rule 10b5-1 plan adopted in September 2025 and scheduled long before recent news.
Chief Executive R.J. Scaringe’s activity fits the same pattern: 34,818 shares at $15.00 on May 28 and 21,446 at $16.17 on April 14, also under a 10b5-1 plan. He still directly holds approximately 922,000 shares, plus additional holdings through trusts and LLCs.
The eye-catching May 15 cluster at $14.52 (McDonough: 38,640; Scaringe: 44,034; Callahan: 42,082; Venkataratnam: 17,486; Gomez: 3,752) was tax withholding on RSU vesting. In other words, mechanical. The June 22 grants of 17,445 shares each at $0.00 to six directors reflect annual equity compensation rather than open-market conviction signals. Officers also picked up small lots via the employee stock purchase plan at $11.6705, priced at 85% of close.
The Signal Buried in the Noise One transaction cut against the grain. Director Aidan Gomez bought 18,000 shares at $13.97 on May 15, 2026, in the open market, near 52-week-low territory. That represents a meaningful open-market purchase near the 52-week low of $11.57.
Furthermore, beneficial owner Volkswagen acquired 62,889,522 shares at $15.90 on April 30, 2026, via private placement, taking its stake to roughly 15.9%. A 10% owner committing that capital is the strongest insider signal in this filing set.
Retail Is Reading It Backwards A widely shared r/stocks post captured the mood: “My bag of RIVN is down about 90% post-IPO… I only own RIVN out of the ones listed, and do not plan on ever buying an IPO again.” Yet the stock is up 44.8% over the past year to $18.63, though the consensus analyst price target is just $18.19. The consensus rating is Hold, with analyst sentiment unchanged since May.
What Actually Matters Next Fundamentals justify caution. Cash fell to $2.845 billion in Q1 2026, with free cash flow of −$1.075 billion, and 2026 adjusted EBITDA guidance of −$2.10 billion to −$1.80 billion. Scaringe framed the setup this way: “With the launch of R2, we are excited to dramatically expand our market opportunity and have more people driving Rivians.” Keep an eye on R2 delivery cadence, the Georgia loan draw, and Uber’s staged investments. The insider activity is more constructive than the headline sales suggest.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.
INCY discovers, develops, and sells proprietary therapeutics focused on hematology, oncology, inflammation, and autoimmunity. The company’s first-quarter fiscal 2026 earnings report, INCY showed $1.27 billion in quarterly revenue (a 21% year-over-year gain) led by Jakafi ($758 million) and Opzelura ($143 million), net sales of $1.1 billion (a 20% rise), and offered annual net sales guidance of up to $4.94 billion, representing a 13% jump from the prior year. To expand its hematology business, the company also recently acquired a therapeutics firm focused on bleeding disorders.
It’s no wonder INCY shares are up 15% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.
Institutions Buying Incyte Institutional volumes reveal plenty. In the last year, INCY has endured some choppiness. But it’s once again enjoying strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in INCY shares. They reflect our proprietary inflow signal, pushing the stock higher:
Source: www.moneyflows.com Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Incyte.
Incyte Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, INCY has had strong sales and earnings growth:
Also, EPS is estimated to ramp higher this year by +16.3%.
Now it makes sense why the stock has been generating Big Money interest. INCY has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
Incyte has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
In the last year, INCY has drawn three outlier inflow signals and is up 70.7%. The blue bars below show when INCY was a top pick on the Outlier 20 report…Big Money support matters:
Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Incyte Price Prediction The INCY action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in INCY at the time of publication.
If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Dick's Sporting Goods (DKS - Free Report) DICK’S Sporting Goods Inc. was founded in 1948 in New York under the labels Dick's Clothing and Sporting Goods, Inc. It was earlier reincorporated as a Delaware corporation and changed our name to Dick's Sporting Goods, Inc. in April 1999. The company’s executive office is located in Coraopolis, Pennsylvania.
DKS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Retail-Wholesale stock. DKS has a Momentum Style Score of B, and shares are up 8.5% over the past four weeks.
Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2027. The Zacks Consensus Estimate has increased $0.00 to $14.24 per share. DKS boasts an average earnings surprise of +0.9%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DKS should be on investors' short list.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about Interactive Brokers Group, Inc. (IBKR - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Interactive Brokers currently has an average brokerage recommendation (ABR) of 1.40, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 10 brokerage firms. An ABR of 1.40 approximates between Strong Buy and Buy.
Of the 10 recommendations that derive the current ABR, eight are Strong Buy, representing 80% of all recommendations.
Brokerage Recommendation Trends for IBKR
Check price target & stock forecast for Interactive Brokers here>>>
The ABR suggests buying Interactive Brokers, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in IBKR?In terms of earnings estimate revisions for Interactive Brokers, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $2.46.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Interactive Brokers. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Interactive Brokers.
After reaching an important support level, Travel + Leisure Co. (TNL - Free Report) could be a good stock pick from a technical perspective. TNL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.
There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.
This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.
Over the past four weeks, TNL has gained 8.5%. The company currently sits at a #3 (Hold) on the Zacks Rank, also indicating that the stock could be poised for a breakout.
The bullish case only gets stronger once investors take into account TNL's positive earnings outlook for the current quarter. There have been 2 upward revisions compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.
Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on TNL for more gains in the near future.
Key Takeaways KNSL gains from strong E&S market demand and low double-digit rate increases across its business. Proprietary technology, analytics and disciplined underwriting support lower loss ratios, and profitability. KNSL combines dividend growth with share buyback, including $62.5 million of buybacks in first-quarter 2026. Kinsale Capital Group, Inc. (KNSL - Free Report) has been trading above its 50-day simple moving average (SMA), signaling a short-term bullish trend. Its share price, as of July 2, 2026, was $354.85, down 30.8% from its 52-week high of $512.76.
The 50-day SMA is a key indicator for traders and analysts to identify support and resistance levels. It is considered particularly important as this is the first marker of an uptrend or downtrend.
Image Source: Zacks Investment Research
With a market capitalization of $8.18 billion, the average number of shares traded in the last three months was 0.3 million.
KNSL’s Price PerformanceShares of this property and casualty insurer have lost 25.5% over the past year against the industry’s 3.6% growth.
Image Source: Zacks Investment Research
KNSL Shares are OvervaluedKinsale Capital shares are trading at a premium to the Zacks Property and Casualty Insurance industry. Its price-to-book value of 4.16X is higher than the industry average of 1.45X.
American Financial Group, Inc. (AFG - Free Report) and Arch Capital Group Ltd. (ACGL - Free Report) shares are also trading at premiums of 2.54 and 1.56, respectively. However, shares of CNA Financial Corporation (CNA - Free Report) are trading at a multiple lower than the industry average. CNA Financial is trading at 1.27.
KNSL’s Growth Projection EncouragesThe Zacks Consensus Estimate for Kinsale Capital’s 2026 earnings per share indicates a year-over-year increase of 5.8%. The consensus estimate for revenues is pegged at $1.92 billion, implying a year-over-year improvement of 2.4%.
The consensus estimate for 2027 earnings per share and revenues indicates an increase of 5.4% and 5.8%, respectively, from the corresponding 2026 estimates.
Earnings have grown 38% in the past five years, better than the industry average of 22.7%. The expected long-term earnings growth rate is 15%, outperforming the industry average of 7.1%.
Kinsale Capital has an impressive Growth Score of B. This style score helps analyze the growth prospects of a company.
Earnings Surprise HistoryKinsale Capital surpassed earnings estimates in each of the last four quarters, the average being 8.88%.
KNSL’s Favorable Return on CapitalKinsale Capital’s return on equity (ROE) of 25.8% for the trailing 12 months compared favorably with the industry’s 7.4%, reflecting the company’s efficiency in utilizing shareholders’ funds. This insurer targets mid-teens ROE over the long term.
Also, return on invested capital (ROIC) has been increasing over the last few quarters as the company raised its capital investment over the same time frame, reflecting KNSL’s efficiency in utilizing funds to generate income. KNSL’s ROIC of 22.7% for the trailing 12 months compared favorably with the industry’s 5.7%.
Average Target Price for KNSL Suggests UpsideBased on short-term price targets offered by nine analysts, the Zacks average price target is $348.33 per share. The average suggests a potential 0.8% upside from the last closing price.
What’s Driving KNSL StockA strong presence across the excess and supply (E&S) market in the United States and high retention rates stemming from contract renewals should drive improved premiums. Management noted that the E&S market has grown significantly and generated better underwriting results than the broader P&C industry. It remains well-positioned to benefit from continued market dislocation, aiding improved submission flows and better pricing decisions.
KNSL has been successfully delivering improved margins and lower loss ratios. The insurer targets clients with small and medium-sized accounts with better pricing and is less prone to competition. Management estimates low double-digit rate increases across the book of business.
Kinsale Capital enjoys the best combination of high growth and low combined ratio among its peers. It targets a combined ratio in the mid-80s range over the long term.
KNSL is well-positioned to generate an improved expense ratio, given its proprietary technology platform, which is likely to provide it with a competitive edge over other industry players and scalability in business. The insurer drives profitability and operational efficiency using analytics.
Despite a low-interest-rate environment, investment income should benefit from the investment of excess operating funds.
Notably, its free cash flow conversion has remained more than 85% over the last few quarters, reflecting its solid earnings.
ConclusionKinsale Capital is poised to gain from its focus on the E&S market, prudent underwriting, lower expense ratio, growth in the investment portfolio and effective capital deployment.
The insurer has an impressive dividend history, increasing dividends since 2017 at an eight-year CAGR of 33%, riding on the strength of operational excellence that supports a solid capital position. As part of wealth distribution, Kinsale Capital repurchased $62.5 million worth of shares during the first quarter of 2026 and had $187.5 million remaining under its repurchase authorization as of March 31, 2026, supporting ongoing capital return alongside organic growth. All these shareholder-friendly moves make the stock an attractive investment pick.
However, given its expensive valuation, it is better to wait for some more time before taking a call on this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Německé akcie měřené indexem DAX (+0,78 %) zakončily poslední seanci toho týdne v zelených číslech.
Z jednotlivých titulů byl v pozornosti investorů Siemens poté, co Kepler Cheuvreux zvýšil doporučení na „hold“ z „reduce“ a cílovou cenu zvýšil na 280 EUR z předchozích 255 EUR. Analytik William Mackie změnu zdůvodnil oceněním akcie před výsledky za 3Q, které Siemens zveřejní 6. srpna. Akcie Siemens připsaly 2,6 %. Analytici z Morgan Stanley zároveň navýšili cílovou cenu akcií E.ON na 22 EUR z 21,50 EUR a ponechali doporučení „overweight“. Banka očekává v aktuální výsledkové sezoně u utilit převážně pozitivní výsledky. Akcie E.ON +4,4 %.
Rheinmetall vyčíslil dopad zrušení německého námořního kontraktu na šest protiponorkových lodí F126 až na 300 mil. EUR tržeb v roce 2026. Analytička Marie-Ange Riggio z Morgan Stanley označila aktualizaci za uklidňující, protože firma nadále čeká meziroční růst tržeb přes 60 %. Banka JPMorgan naopak snížila cílovou cenu na 1350 EUR z 1500 EUR a upozornila na vyšší realizační rizika, přesto Rheinmetall dál vnímá jako nejrychleji rostoucí obrannou firmu ve svém pokrytí. Akcie společnosti Rheinmetall odepsaly 1,9 %.
Evropský index STOXX 600 se pohybuje v kladném teritoriu a posiluje o 0,71 %. V rámci sektorů se nejvíce daří IT (+2,38 %), utilitám (+1,69 %) a průmyslu (+1,37 %). Naopak největší ztráty zaznamenává nezbytná spotřeba (-0,20 %), zdravotnictví (-0,17 %) a zbytná spotřeba společně s realitami shodně (-0,02 %).
Index DAX +0,78 % na 25779,31 b. Nejsilnější akcie Změna Nejslabší akcie Změna E.ON (EOAN) +4,4 % Scout24 SE (G24) -2,0 % HOCHTIEF AG (HOT) +2,7 % Rheinmetall AG (RHM) -1,9 % Siemens (SIE) +2,6 % SAP (SAP) -1,5 % GEA Group AG (G1A) +2,3 % Merck (MRK) -1,3 % Daimler Truck Holding AG (DTG) +2,2 % Qiagen (QIA) -1,0 %
Zdroj: Bloomberg
Warren Buffett is a tough act to follow. He is arguably the greatest investor of his time, transforming Berkshire Hathaway (BRKA +1.41%)(BRKB +1.40%) into a massive holding company with almost 200 subsidiaries and a $330 billion equity portfolio, and he has trounced the S&P 500 over time.
However, Greg Abel, Buffett's handpicked successor, made his mark on the company in the first quarter of 2026, his first as CEO. Here's what it looks like, and how it could change the company's trajectory.
Image source: Getty Images.
Out with the old In his first annual shareholder letter as CEO, Abel committed to upholding the values that shaped Berkshire Hathaway over the 60 years Buffett ran it. He said that "Berkshire's culture and values remain unchanged and will continue into perpetuity," and he specified the commitment to allocating capital efficiently with a business underpinned by a robust insurance operation. He echoed Buffett's maxim that the company's job is to be "exceptional stewards of our shareholders' capital."
He laid out the principles behind his investing strategy, which include:
Investing in companies that Berkshire understands and that have durable, long-term economic moats. Choosing partners with integrity who understand their own customers. Avoiding companies that could tarnish Berkshire's reputation and aren't good for society. Acting quickly and concentrating the portfolio in a few, high-conviction stocks. Staying disciplined. In the company's equity positions, Abel followed these principles when he made his moves. Most noticeable was the immediate termination of most of its smaller positions, followed by a dive straight into the fourth principle to consolidate the portfolio into fewer high-conviction positions. The equity portfolio went from 42 to 29 positions, the lowest number in more than a decade.
Today's Change
(
1.40
%) $
6.97
Current Price
$
506.71
In with the new Abel also expanded the company's position in Alphabet, which is a rare tech stock in the portfolio. One of the stocks closed out was Amazon, so Berkshire remains with two artificial intelligence (AI) stocks, the other being perennial Buffett favorite Apple. Apple can be viewed as a consumer goods company, but Alphabet is more of a pure-play tech stock.
While the portfolio is still highly invested in consumer goods and financial stocks, and the new positions in Macy's and Delta Air Lines are classic Buffett-style stocks, it could signal that Abel feels more comfortable understanding Alphabet and its role in the economy. As the shift to digital and AI continues at a rapid pace, it appears that Abel is willing to invest in it.
Jennifer Saibil has positions in Apple. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, and Berkshire Hathaway. The Motley Fool recommends Delta Air Lines. The Motley Fool has a disclosure policy.
American Electric Power is positioned to benefit from surging data center-driven electricity demand, underpinned by robust contracted load growth. AEP guides for 7–9% earnings growth, supported by a $78 billion five-year capital plan targeting transmission and generation expansion. Shares trade at a forward P/E of 21.8, above the historical average, yet this premium is justified by strong visibility into future growth and contracted demand.
EPR Properties (EPR - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EPR broke out above the 50-day moving average, suggesting a short-term bullish trend.
The 50-day simple moving average is one of three major moving averages used by traders and analysts to determine support or resistance levels for a wide range of securities. But the 50-day is considered to be more important because it's the first marker of an up or down trend.
EPR has rallied 5.2% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests EPR could be on the verge of another move higher.
The bullish case only gets stronger once investors take into account EPR's positive earnings estimate revisions. There have been 5 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.
Investors should think about putting EPR on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
EPR Properties (EPR - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, EPR broke through the 20-day moving average, which suggests a short-term bullish trend.
The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.
The 20-day moving average can show signals that are similar to other SMAs as well. If a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.
EPR has rallied 5.2% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests EPR could be on the verge of another move higher.
The bullish case solidifies once investors consider EPR's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 5 higher, while the consensus estimate has increased too.
Investors should think about putting EPR on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: UMB Financial (UMBF - Free Report) Headquartered in Kansas City, MO, UMB Financial Corporation provides banking services and asset servicing in the United States. Its banking subsidiary — UMB Bank, National Association — offers banking, asset management, trust, credit card and cash-management services to commercial, retail, government and correspondent-bank customers.
UMBF is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Finance stock. UMBF has a Momentum Style Score of A, and shares are up 11.7% over the past four weeks.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $12.76 per share. UMBF boasts an average earnings surprise of +17.4%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, UMBF should be on investors' short list.
Key Takeaways SPX Technologies ended Q1 2026 with a $755M HVAC backlog, up 38% organically YoY.Data center cooling demand and higher production throughput drove HVAC organic growth in Q1.Manufacturing expansions and acquisitions are strengthening SPX Technologies' HVAC platform. SPX Technologies, Inc.’s (SPXC - Free Report) HVAC business appears well positioned to sustain growth over the next several years, supported by a sharp increase in backlog, capacity expansion initiatives, strategic acquisitions and durable demand from data center cooling and commercial HVAC markets. The company ended the first quarter of 2026 with an HVAC backlog of $755 million, up 38% organically year over year, providing strong revenue visibility while reinforcing confidence that favorable market conditions can extend well beyond 2026.
One of the strongest structural growth drivers remains the rapid expansion of AI infrastructure and hyperscale data centers. SPXC continues to benefit from elevated demand for cooling products used in these facilities, where higher computing densities require increasingly sophisticated thermal-management solutions. During the first quarter, HVAC organic growth benefited from higher data center cooling volumes and improved throughput from recent capacity additions. These trends indicate that demand is being supported by both favorable end-market conditions and the company's improved manufacturing capabilities.
To meet rising demand, SPX Technologies has continued investing in manufacturing expansion across its HVAC operations. The company began producing highly engineered aluminum dampers at TAMCO’s new Tennessee facility in the first quarter and expects production to ramp through the year. It also started OlympusMAX production in Olathe, KS. Its Madison, AL, build-out is also progressing, with assembly expected in the second half of 2026 and initial production in the first half of 2027. These investments should improve throughput and help SPXC convert backlog into revenues.
Organic growth is also being complemented by targeted acquisitions that strengthen SPXC's HVAC platform. Over the past year, the company added Sigma & Omega, Thermolec and Crawford's commercial air-handling operations, expanding its presence across hydronic heating, electric duct heating, commercial air handling and engineered HVAC equipment. Beyond broadening the product portfolio, these acquisitions create opportunities for commercial synergies, procurement efficiencies and expanded manufacturing capabilities that should support long-term growth.
Taken together, SPXC's $755 million HVAC backlog, manufacturing investments, strategic acquisitions and exposure to durable secular growth trends suggest that its HVAC business is supported by more than a temporary surge in orders. Successful execution on capacity expansion and acquisition integration will remain important, but the company's strong backlog visibility provides a solid foundation that could sustain HVAC growth well into 2028.
How SPXC Stacks Up Against HVAC PeersSPX Technologies operates in a competitive HVAC market where demand for data center cooling, modular construction and high-performance building systems is drawing strong participation from peers such as Comfort Systems USA, Inc. (FIX - Free Report) and AAON, Inc. (AAON - Free Report) . Like SPXC, both companies are benefiting from strong technology-sector demand, expanding backlog and capacity investments tied to data center and advanced HVAC opportunities.
Comfort Systems is gaining from robust demand across mechanical and electrical solutions for technology customers. The company ended the first quarter of 2026 with a record backlog of $12.5 billion, up $5 billion from a year ago, supported by strong tech-sector demand. Advanced technology, dominated by data center work, accounted for 56% of revenues, while modular revenues represented 17% of total revenues. Comfort Systems is also expanding modular capacity, targeting 4 million square feet by the end of 2026, strengthening its ability to support large-scale data center construction.
AAON is also benefiting from strong data center thermal-management demand through its highly engineered HVAC and cooling solutions. The company reported a backlog of $2.1 billion, more than double year over year, with Basics-branded orders up 160% from the prior year and book-to-bill above 2. Basic sales grew 72% year over year, supported by data center demand and higher production from expanded facilities in Longview, Memphis and Redmond. AAON continues investing in capacity and expects Basics revenues to reach roughly $1 billion in 2026, with longer-term capacity potential above $2 billion.
SPXC Stock’s Price Performance & Valuation TrendShares of SPXC have climbed 31.6% in the past year, outperforming the broader Construction sector and the S&P 500 Index but underperforming the Zacks Building Products - Air Conditioner and Heating industry.
Image Source: Zacks Investment Research
SPXC stock is currently trading at a discount compared with the industry, with a forward 12-month price-to-earnings (P/E) ratio of 26.79, as evidenced by the chart below.
Image Source: Zacks Investment Research
Earnings Estimate Trend for SPXCSPXC’s earnings estimates for 2026 and 2027 have trended upward in the past 60 days. The estimated figures for 2026 and 2027 imply year-over-year growth of 18.1% and 12.9%, respectively.
Image Source: Zacks Investment Research
SPX Technologies stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Every year in the United States, roughly 100,000 people sit on transplant waiting lists. Some will wait years. Others won't make it. The problem isn't only a shortage of willing donors; it's that the organs that do become available often don't survive long enough to reach the right recipient. The traditional method of packing organs on ice gives surgeons a brutal clock to work against: A harvested heart, for example, may only have four to six hours before it's no longer viable.
TransMedics Group (TMDX +1.46%) is dismantling that constraint, and almost nobody is talking about it in the way they should be. TransMedics makes the Organ Care System (OCS), a portable machine that keeps donor organs warm, perfused with oxygenated blood, and in a functional metabolic state -- essentially keeping them alive outside the body during transport. Instead of racing the clock, surgeons can assess organ quality in real time before committing to a transplant. That changes everything about how transplant medicine works.
But what makes TransMedics genuinely interesting to me as a long-term investment isn't just the device. The company has spent years building the infrastructure around it. It's called the National OCS Program (NOP), and it's essentially a vertically integrated logistics operation, with its own fleet of 22 fixed-wing aircraft, coordination with ground transportation, and a clinical team that travels with each organ. Think of it less like a medical device company and more like a specialized logistics network that happens to transport living human organs.
That's a business model that competitors can't easily replicate with a single product launch.
Today's Change
(
1.46
%) $
0.99
Current Price
$
68.84
What the next decade could look like The kidney transplant market is where the 10-year story gets truly interesting. Kidney disease is the most common condition requiring a transplant. There are over 90,000 people waiting for kidneys in the U.S. alone, and TransMedics is actively developing an OCS Kidney program. If the company can crack kidney preservation and logistics the same way it has with hearts, livers, and lungs, the addressable market expands dramatically.
Then there's Europe. TransMedics recently announced a strategic investment in PAD Aviation, a Germany-based private aviation operator, with the explicit goal of replicating the U.S. NOP model across European transplant centers. The company also announced a ground transportation collaboration in Italy using Mercedes-Benz vehicles.
By 2035, it's realistic to imagine TransMedics as the dominant infrastructure provider for organ transplantation across the U.S. and much of Europe, with a kidney program that has opened a market significantly larger than its current organ mix.
None of this is guaranteed. TransMedics has been investing heavily in expansion, and operating expenses jumped meaningfully in the most recent quarter as the company scales its European ambitions. Gross margin compressed slightly year over year in the first quarter of 2026. If growth slows before the European NOP generates returns, the spending profile becomes harder to defend.
A good example of this has come over the last six months, during which shares have fallen by roughly 45%. Most of it came after a Q1 2026 earnings miss, in which profits were well below expectations. In my opinion, the culprit here wasn't the business breaking; it was spending. The company is simultaneously scaling while advancing the kidney program and building out clinical teams. That costs money, and Wall Street punished the margin compression hard.
But revenue still grew 21% year over year. To me, a company aggressively building proprietary infrastructure in a market it essentially created isn't a red flag -- it's exactly what you want to see.
Image source: Getty Images.
My take To me, TransMedics is one of the more unusual companies in healthcare and tech right now. It's building something that looks less like a device business and more like a category-defining network. The OCS itself is the entry point, but the logistics infrastructure, like the aircraft, the teams, and the coordination, is what actually creates a moat.
In 10 years, if the kidney program delivers and Europe scales, this company could look dramatically different in size and reach than it does today. Investors willing to hold through near-term margin noise may be rewarded.
Key Takeaways EMCOR's electrical construction revenues rose 33.1% to a record $1.45B in first-quarter 2026.Network and communications revenues surged nearly 50% on AI infrastructure and data-center demand.EMCOR's remaining performance obligations reached a record $15.62B on strong market bookings. EMCOR Group's (EME - Free Report) electrical construction business continues to build strong momentum, supported by robust demand for mission-critical infrastructure and the company's ability to execute complex projects at scale. In the first quarter of 2026, the segment delivered record revenues of $1.45 billion, up 33.1% year over year, while maintaining an industry-leading operating margin of 12.1%. Although margins eased slightly due to acquisition-related amortization, profitability remained strong, highlighting the resilience of EMCOR's operating model.
The biggest growth driver remains network and communications, where revenues surged nearly 50% as hyperscalers and enterprises accelerated investments in AI infrastructure and data centers. Beyond this, EMCOR benefited from healthy demand across institutional projects, hospitality and entertainment, including stadium construction, as well as higher volumes of short-duration projects and service work. This broad-based demand reduces reliance on any single end market and supports sustainable long-term growth.
Looking ahead, management expects the momentum to continue. Remaining performance obligations climbed to a record $15.62 billion, driven by strong bookings across data centers, healthcare, institutional, water and wastewater and manufacturing markets. The company also continues expanding its geographic footprint while leveraging prefabrication, virtual design, workforce training and disciplined contract management to improve execution on increasingly complex projects.
With AI-driven data center construction showing no signs of slowing and diversified demand across multiple infrastructure markets, EMCOR's electrical construction segment appears well-positioned to remain a key contributor to the company's growth throughout 2026 and beyond.
How Do EMCOR's Peers Compare in Electrical Construction?Two of EMCOR's closest competitors in electrical and mechanical contracting are Quanta Services (PWR - Free Report) and Comfort Systems USA (FIX - Free Report) . Both companies are benefiting from the same secular drivers, including AI data center construction, grid modernization and expanding infrastructure investment.
Quanta continues to strengthen its electrical construction business through large-scale transmission, substation and renewable energy projects, while also increasing its exposure to data centers and communications infrastructure. Quanta has leveraged its engineering expertise and nationwide workforce to secure long-duration projects, giving it strong revenue visibility. As AI-related power demand rises, Quanta is expected to remain a key beneficiary of utility and hyperscaler spending.
Comfort Systems is also expanding its presence in mission-critical facilities through electrical, mechanical and building automation services. Comfort Systems has steadily increased its exposure to data centers, semiconductor manufacturing and advanced industrial facilities, supported by strategic acquisitions. Comfort Systems further benefits from higher-margin service work and prefabrication capabilities that improve execution and profitability.
While both Quanta and Comfort Systems are well-positioned, EMCOR's diversified project portfolio, disciplined contract management and broad geographic reach provide it with a strong competitive position in the rapidly growing electrical construction market.
EME’s Price Performance, Valuation & EstimatesShares of EMCOR have gained 26.6% year to date (YTD), underperforming the Zacks Building Products - Heavy Construction industry, as shown below.
EME YTD Price Performance
Image Source: Zacks Investment Research
From a valuation standpoint, EME stock trades at a forward 12-month price-to-earnings ratio of 24.9, below the industry’s average.
EME Valuation - P/E (F12M)
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for EME’s 2026 sales and earnings implies year-over-year growth of 12% and 13.5%, respectively. Earnings per share estimates for 2026 have increased to $29.37 in the past 30 days, as shown below.
Image Source: Zacks Investment Research
EMCOR currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Invesco (IVZ - Free Report) Headquartered in Atlanta, GA, Invesco Ltd. operates as an independent investment manager and offers a wide range of investment products and services. The company was incorporated in 1935. As of March 31, 2026, Invesco served clients in more than 120 countries and had AUM worth $2.16 trillion.
IVZ is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. IVZ has a Growth Style Score of B, forecasting year-over-year earnings growth of 27.6% for the current fiscal year.
Three analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $2.59 per share. IVZ also boasts an average earnings surprise of +7.9%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, IVZ should be on investors' short list.
As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (MRNA +9.99%) and Recursion Pharmaceuticals (RXRX +3.54%) offer two distinct paths forward.
Moderna pioneered the use of messenger RNA to deliver genetic instructions to cells, while Recursion uses machine learning to identify new drug candidates. Both companies are currently operating at a net loss while investing heavily in research, making them high-stakes options for those tracking the future of the healthcare sector.
The case for ModernaModerna focuses on developing mRNA medicines that instruct the human body to produce proteins to prevent or treat various diseases. The company is diversifying its pipeline into immuno-oncology and rare diseases through strategic collaborations with partners such as Merck & Co. (MRK +3.13%) and Recordati. These partnerships are vital for its research and commercialization efforts as it moves beyond its initial focus on respiratory viruses.
In FY 2025, the company reported revenue of more than $1.9 billion, a decrease of approximately 40% from the previous fiscal year. This decline contributed to a net loss of roughly $2.8 billion for the period, though it was narrower than in fiscal 2024.
On its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This ratio measures total debt relative to shareholders’ equity, with lower ratios typically indicating less reliance on borrowed money. Free cash flow, calculated as cash from operations minus capital expenditures, was nearly $2.1 billion negative.
The case for Recursion PharmaceuticalsRecursion Pharmaceuticals operates as a clinical-stage "TechBio" company that uses its AI-native operating system to discover new medicines. It maintains critical partnerships with major biotech stocks and pharmaceutical firms like Roche, Genentech, and Sanofi (SNY +3.67%). These collaborations provide funding and validation for its automated biological research platform as it targets high-unmet-need areas like neuroscience.
In FY 2025, the company generated revenue of approximately $74.7 million, marking an increase of about 27% year over year. Despite this growth, it recorded a net loss of nearly $645 million for the fiscal period, as the firm continued to invest heavily in its digital and laboratory infrastructure.
As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of near 0.1x, indicating a strong position to meet short-term liabilities. Free cash flow for the period was approximately negative $378 million, reflecting the high costs of maintaining its data-generation capabilities and proprietary hardware.
Risk profile comparisonModerna faces intense competitive pressure from large manufacturers like Pfizer (PFE +1.78%), Sanofi, and GSK (GSK +4.66%). Changes in regulatory policies or vaccine recommendations can significantly shift demand and disrupt financial forecasts. While a major $2.25 billion lawsuit with Genevant and Arbutus Biopharma Corp (ABUS +2.96%) was settled in March 2026, the company still navigates industry-wide uncertainty regarding mRNA intellectual property. Success depends on high-risk clinical execution across its oncology and rare disease programs.
Recursion Pharmaceuticals relies heavily on its unproven AI-enabled discovery platform, where any inaccuracies in predictive modeling could lead to failed drug candidates. The business is also dependent on strategic partners such as Roche to fund research, so any termination of these deals would harm operations. Additionally, the company faces risks from potential cyber-attacks on its proprietary biological data sets and its reliance on third-party cloud infrastructure provided by Amazon.com Inc (AMZN +0.55%).
Valuation comparisonModerna offers a more established revenue base and a lower sales multiple, whereas Recursion Pharmaceuticals is a higher-growth, earlier-stage bet with a steeper price-to-sales valuation.
MetricModernaRecursion PharmaceuticalsSector BenchmarkForward P/En/an/a389.1xP/S ratio12.9x26.8xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
The COVID-19 vaccine developed by Moderna was a proof of concept of the power of mRNA research to quickly produce new treatments. Unfortunately for Moderna, the decline in people getting the COVID vaccine, along with plenty of competitors with their own vaccines, has hammered the business’s revenue in recent years. A more recent RSV vaccine reached the market after competing vaccines, resulting in less-than-robust adoption.
Still, Moderna has some 25 mRNA Development candidates across 35 development programs in its portfolio. Seeing those come to market and make a meaningful impact on the business will take some time, however. Next year is likely when one or more of the products will get to market, and it is probably not until 2028 that significant revenue will hit the top line. In fiscal 2026, Moderna is seen posting modest sales growth of about 8% to get close to $2.1 billion revenue with a much narrower net loss of around $1.8 billion.
Recursion, meanwhile, is still in development phase, with lumpy revenue stemming from milestone payments from partners like Sanofi. For fiscal 2026, revenue is expected to decline about 11% due to lower milestone payments. The business is making progress with its AI-based discovery platform. In the first quarter, management touted its first clinical proof of concept with its polyp-related treatment, REC-4881 allosteric MEK1/2 inhibitor focused on FAP. It showed a significant reduction in precancerous polyps, a major driver of the disease’s progressive nature. Still, significant revenue for the business is seen as years away.
So which cutting-edge biotech is the stock to buy? Moderna has come to market with proven treatments derived from its mRNA platform, and Recursion is still hoping to prove its model. Moderna may be in a sales and development lull for 2026, but odds are a proven formula will provide itself again. Moderna gets the nod here.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Wesco International (WCC - Free Report) WESCO International, Inc. is one of the largest players in the highly fragmented distribution market for electrical construction products in North America.
WCC is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 19.31; value investors should take notice.
One analyst revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.14 to $15.94 per share. WCC also boasts an average earnings surprise of +3.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, WCC should be on investors' short list.
XRP has gradually erased its bull run gains over the past eleven months and now trades at a crucial Fibonacci level that holds significance to its bull structure.
XRP enters July 2026 at what many see as its most important technical point since the start of the bull run. The asset had earlier climbed from about $1.05 in the second week of November 2024 into an all-time high of $3.66 in July 2025.
However, since then, it has spent eleven months gradually losing these gains. Now, XRP trades at $1.1, sitting just above the 1.0 Fibonacci retracement level at $1.00795.
This level is important because it marks a full return to the starting point of the entire rally. Although the first weekly candle of July shows a 5.07% gain, the broader chart structure suggests that the situation is still fragile.
The Final Fibonacci Support for XRP Toward the end of June, XRP fell to $1.009, its strongest test of the $1 level since November 2024. Slightly below this, the 1.0 Fibonacci level at $1.00795 reflects a complete retracement from the cycle low to the July 2025 peak.
Throughout the eleven-month decline since August 2025, XRP lost key Fibonacci levels one after another. The 0.382 level at $2.65117, the 0.618 at $2.02366, the 0.786 at $1.57696, and the 0.888 at $1.30575 all broke down and flipped to resistance.
XRP Fibonacci Resistance and Support Levels If XRP manages to hold above $1.00795 on a weekly closing basis, it could give buyers a base to build from. However, if it drops below this level, bears will have an opportunity to start targeting sub-$1 levels.
Specifically, the $0.8 to $0.9 range could act as the immediate defense. Below this, the 1.13 extension at $0.66229 becomes the next support, followed by the 1.272 extension at $0.28472. These levels suggest possible declines of 82% and 92% from the July 2025 peak.
Downtrend Still in Control Meanwhile, a descending trendline that started from the July 2025 peak continues to limit every recovery attempt and confirms that the downtrend remains in control despite the mild July rebound.
XRP Weekly Descending Trendline XRP recently reached a weekly high of $1.11, as buyers started testing the resistance at the trendline. However, the price pulled back slightly to $1.09969, leaving the breakout uncertain. A confirmed weekly close above this trendline would be the first sign of a shift in structure since the peak.
So far, this trendline has held firm. Every bounce since August 2025 has failed at or before reaching it. Until XRP breaks above it, the overall trend remains bearish.
XRP Faces Resistance from the Ichimoku Cloud Also, the weekly Ichimoku Cloud presents further resistance above the current price. The Tenkan-sen stands at $1.27885, while the Kijun-sen is at $1.71205. Both are well above current levels, showing that momentum has not yet turned positive.
For any recovery to continue, XRP must first move above the Tenkan-sen at $1.27885 and then push toward the Kijun-sen at $1.71205. Only after that can it begin to challenge the cloud itself.
XRP Ichimoku Cloud The projected cloud spans from Senkou Span A at $1.49545 to Senkou Span B at $2.33696, covering a wide range of $0.84. This wide zone shows strong resistance ahead.
For XRP to break above the cloud at $2.33696, it would need to overcome all remaining Fibonacci levels, move above four major moving averages, and clear the entire cloud structure. This makes a near-term move toward the 0.382 level at $2.65117 a very ambitious scenario.
Early July Signals and What Comes Next The first July weekly candle shows some positive signs. XRP opened at $1.04646, reached a high of $1.11, and now trades at $1.1.
On-chain data also shows the market boasts some strength. Specifically, XRP spot ETF inflows have stayed positive for eight straight weeks. In the week of June 26, inflows reached $22.99 million, bringing total net inflows to $1.47 billion.
Meanwhile, exchange outflows rose from 40.7 million XRP on June 22 to around 123 million XRP in later sessions. This nearly 200% increase suggests that larger players may be accumulating. Still, the market faces substantial risks.
For XRP to recover, it must move through key resistance levels step by step. The first target is the 0.888 Fibonacci level at $1.30575, which sits close to the Tenkan-sen at $1.27885. After that, the next level to watch is the 0.786 at $1.57696.
However, XRP still trades below its 20-day EMA at $1.11, 50-day EMA at $1.20, 100-day EMA at $1.31, and 200-day EMA at $1.52. These levels form a strong barrier that the asset must overcome to confirm any lasting recovery.
DisClamier: This content is informational and should not be considered financial advice. The views expressed in this article may include the author's personal opinions and do not reflect The Crypto Basic opinion. Readers are encouraged to do thorough research before making any investment decisions. The Crypto Basic is not responsible for any financial losses.
Key Takeaways IQVIA's AI tools, historic R&D backlog and robust free cash flow support its growth outlook.IQV's $34.2B R&D backlog includes $8.9B expected to convert to revenues in the next 12 months.IQVIA faces risks from past industry turmoil, no cash dividend plans and weak liquidity. Shares of IQVIA (IQV - Free Report) have jumped 26.1% over the past year, compared with the industry’s 10.4% decline and the Zacks S&P 500 Composite's 24.3% rise.
1-Year Share Price Performance Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 revenues is $17.3 billion. The metric is expected to gain 5.8% year over year. The same growth rate is anticipated for the top line in 2027. The consensus mark for 2026 EPS is set at $12.8, suggesting a 7.4% increase from that reported in the preceding year. For 2027, the expected growth rate is 11.2%.
Factors That Augur Well for IQV’s SuccessAI Enhances Data Integration: IQVIA’s ability to process information is enhanced by recent advancements in AI, including IQVIA.ai, which provides clients with a single point of access to their AI solutions and enables them to explore a broader portfolio. It has built deep industry trust, as evidenced by 19 of the top 20 global pharma companies utilizing IQV’s distinguished AI agents in their workflows.
Life science clients are highly inclined to select IQVIA’s AI-ready data foundations, including 192 specialized AI agents deployed in the field across 64 use cases in Commercial Solutions and R&D Solutions. Large pharma companies leverage IQVIA’s Data-as-a-Service platform to harmonize global commercial intelligence.
Historic Backlog & Pipeline: IQVIA’s growth trajectory is immensely dictated by its record-breaking R&D Solutions backlog of $34.2 billion. It provides a stream of recurring revenues that enhances long-term visibility. During the first-quarter 2026 earnings call, Ari Bousbib, the CEO and chairman, stated that $8.9 billion of the total backlog is expected to convert into revenues over the next 12 months, marking an 8% rise from the year-ago quarter’s actual.
Immaculate Earnings Quality: As of March 31, 2026, IQV registered $618 million in cash flow from operations and incurred $127 million in CapEx, leading to a free cash flow (FCF) of $491 million. This robust FCF represents 100% of adjusted net income. As a result, IQVIA’s balance sheet accrual ratio was pushed downward to -0.9, wider than the industry’s -0.5, verifying high earnings quality.
Shareholder-Friendly Strategy: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In the past year alone, the company repurchased shares worth $1.24 billion. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock.
Risks Faced by IQVIAPast Industry Turmoil: During the first-quarter 2026 earnings call, management stated that the company is coming out of 3-4 years of industry turbulence. It is primarily fueled by a post-COVID deflationary environment affecting budgets, the IRA under the Biden administration and policies announced/enacted during the Trump regime. These factors collectively forced large pharma to halt discretionary spending that had driven historic organic growth.
No Dividend Discourages Investors: The company currently has no plan to pay out cash dividends on common stock. Payment of dividends in the future depends on factors such as its financial condition, cash requirements and contractual restrictions. Investors seeking cash dividends should avoid buying the IQVIA stock.
Weak Liquidity: IQV ended the first quarter of 2026 with a cash chest of $2.1 billion against a current debt of $1.8 billion. While the current debt was a tad bit lower than cash, the larger picture reveals that IQV’s current liabilities position exceeds its current assets.
As a result, the company ended the aforesaid quarter with a current ratio of 0.75, which has stayed below 1 over the past multiple quarters, hinting at a sustained weak liquidity position. The inability to cover short-term debt does not bode well with investors.
IQV’s Zacks Rank & Stocks to ConsiderThe company has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader Zacks Medical sector are Globus Medical (GMED - Free Report) and Integra LifeSciences (IART - Free Report) , currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical has a long-term earnings growth expectation of 10.2%. GMED delivered a trailing four-quarter earnings surprise of 26.3%, on average.
Integra LifeSciences has a long-term earnings growth expectation of 5.9%. IART delivered a trailing four-quarter earnings surprise of 16.8%, on average.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Ensign Group (ENSG - Free Report) Founded in 1999 and headquartered in San Juan Capistrano, CA, The Ensign Group Inc. provides healthcare services in the post-acute care continuum, urgent care center and mobile ancillary segments in the United States.
ENSG is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. ENSG has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $7.53 per share. ENSG boasts an average earnings surprise of +3.4%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ENSG should be on investors' short list.
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Commvault Systems, In
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Let's take a look at what these Wall Street heavyweights have to say about Commvault Systems (CVLT - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Commvault currently has an average brokerage recommendation (ABR) of 1.82, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.82 approximates between Strong Buy and Buy.
Of the 17 recommendations that derive the current ABR, 10 are Strong Buy, representing 58.8% of all recommendations.
Brokerage Recommendation Trends for CVLT
Check price target & stock forecast for Commvault here>>>
While the ABR calls for buying Commvault, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is CVLT Worth Investing In?In terms of earnings estimate revisions for Commvault, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.19.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Commvault. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Commvault.
Key Takeaways United Therapeutics acquired Thymmune, adding preclinical THY-100 for congenital athymia.UTHR paid $140M upfront, with up to $160M tied to clinical and regulatory milestones through 2031.United Therapeutics said the platform complements its UThymoKidney and regenerative medicine programs. United Therapeutics (UTHR - Free Report) announced the acquisition of Thymmune Therapeutics, a Cambridge-based privately held biotech company developing scalable, regenerative thymic cell therapies. The acquisition reinforces UTHR’s commitment to advancing regenerative medicine while expanding the availability and long-term success of organ transplantation.
The acquisition adds THY-100, Thymmune’s lead investigational therapy, to UTHR’s pipeline. The candidate is in preclinical development for congenital athymia, an ultra-rare, life-threatening disorder in which infants are born without a functional thymus. The thymus is a vital organ that develops and trains T-cells, which help protect against infections and diseases.
Beyond congenital athymia, the successful clinical development of THY-100 could unlock broader applications in post-transplant immune tolerance, autoimmune diseases, immunodeficiency disorders and age-related decline in immune function.
Per the agreement, United Therapeutics made an upfront payment of $140 million in cash to Thymmune, subject to customary post-closing adjustments. The deal also includes potential milestone payments of up to $160 million, contingent upon achieving specified clinical and regulatory milestones through the end of 2031.
Year to date, shares of United Therapeutics have rallied 14.1% against the industry’s 5.9% decline.
Image Source: Zacks Investment Research
Thymmune’s proprietary regenerative medicine platform converts human-induced pluripotent stem cells into functional thymic cells. Per UTHR, Thymmune's thymic regeneration platform complements its UThymoKidney clinical development program and enhances its growing portfolio of immunomodulatory and regenerative medicine technologies.
United Therapeutics' expertise in organ alternatives and cell-based technologies makes it an ideal partner to accelerate the development of Thymmune’s thymic regeneration platform and bring transformative therapies to patients with serious immune-mediated diseases.
United Therapeutics has different kinds of organ manufacturing products across four different organs — hearts, kidneys, livers and lungs — in clinical and preclinical development. These include xenotransplantation, 3D organ bioprinting, bio-artificial organs, regenerative medicine and ex vivo lung perfusion.
The company’s xenotransplantation program includes three development-stage organ products, which are intended for transplantion from gene-edited pigs into humans. These include UKidney (derived from a 10-gene-edited source pig), UHeart (derived from a pig with 10 gene edits) and UThymoKidney (derived from a pig with a single gene edit along with tissue from the pig’s thymus).
UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #4 (Sell).
Some other better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents per share. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 6.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 17.3% year to date.
Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.92 from $2.91. LQDA shares have gained 128.9% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Vertex Pharmaceuticals (VRTX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Vertex currently has an average brokerage recommendation (ABR) of 1.53, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 34 brokerage firms. An ABR of 1.53 approximates between Strong Buy and Buy.
Of the 34 recommendations that derive the current ABR, 25 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 73.5% and 5.9% of all recommendations.
Brokerage Recommendation Trends for VRTX
Check price target & stock forecast for Vertex here>>>
While the ABR calls for buying Vertex, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is VRTX a Good Investment?In terms of earnings estimate revisions for Vertex, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $19.15.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Vertex. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Vertex.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Radian (RDN - Free Report) Founded in 1977 and headquartered in Philadelphia, PA, Radian Group is a credit enhancement company that supports homebuyers, mortgage lenders, loan servicers and investors with a suite of private mortgage insurance and related risk-management products and services. Radian trades on the New York Stock Exchange under the symbol RDN.
RDN is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Finance stock. RDN has a Momentum Style Score of B, and shares are up 12.9% over the past four weeks.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.38 to $5.17 per share. RDN also boasts an average earnings surprise of +10.7%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, RDN should be on investors' short list.
Key Takeaways ILMN is focused on core sequencing, multiomics, and software after the GRAIL spin-off.ILMN raised 2026 guidance as Q1 revenues, margins, EPS and NovaSeq X placements topped expectations.ILMN faces China weakness, tariffs and higher input costs that may pressure growth and margins. Illumina Inc. (ILMN - Free Report) is well-poised to grow in the coming quarters owing to its strategic execution against growing the core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing momentum in clinical end markets is boosting sequencing consumables demand. Higher-than-expected NovaSeq X placements and continued transition to the platform further strengthen the outlook. Yet, China remains a drag on Illumina’s growth, while input-cost volatility can limit incremental margin upside over the next several quarters.
Over the past year, this Zacks Rank #3 (Hold) stock has surged 87%, well ahead of the industry’s 23.8% growth and the S&P 500 composite’s rise of 22.8%.
The renowned biotechnology company has a market capitalization of $27.82 billion. ILMN’s earnings yield of 2.8% is well ahead of the industry’s -14.9% yield. In the trailing four quarters, it surpassed estimates on all occasions, delivering an average surprise of 12.2%.
Let’s delve deeper.
Tailwinds Behind ILMN StockSharpened Focus on Core Genomics: Following the spin-off of GRAIL in June 2024, Illumina has continued to center its strategy on the core sequencing franchise while scaling into adjacent multiomics and data offerings. The company remains focused on returning to durable growth and higher profitability, aiming for high-single-digit revenue growth by 2027, along with double-digits to teens annual earnings per share (EPS) growth, anchored by its roadmap of growing the core sequencing business, expanding multiomics and building services, data and software capabilities.
Image Source: Zacks Investment Research
First-quarter 2026 results reinforced that direction, with revenues, margins and non-GAAP EPS exceeding guidance. Management also raised full-year 2026 guidance, now expecting revenues in the range of $4.52-$4.62 billion and non-GAAP diluted EPS in the range of $5.15-$5.30, alongside a modest step-up in the non-GAAP operating margin outlook between 23.4% and 23.6%.
NovaSeq X Placements and Transition Progress: Illumina’s core sequencing business remains anchored by NovaSeq X. First-quarter 2026 placements exceeded 80 units, around 20 more than the prior-year quarter and above the company’s targeted quarterly range. Demand remains strong for the platform, especially with clinical. Management noted supply constraints in meeting first-quarter placement demand while exiting the quarter with a backlog that supported a higher full-year instrument outlook.
Transition progress also continued, with approximately 82% of volumes and 55% of revenues transitioned to NovaSeq X in the first quarter, and roughly 90% of research and applied volume now on the platform. Management continues to plan for average quarterly NovaSeq X placements of 50 to 60 through 2026 while investing to scale supply given the current pipeline.
Clinical Demand Remains the Key Driver: Illumina continues to benefit from the broader adoption of NGS-based testing, with clinical markets now representing the majority of sequencing consumables revenues in first-quarter 2026. Management cited continued adoption of sequencing-based diagnostics and growing use of sequencing-intensive tests, including comprehensive genomic profiling and whole genome sequencing, as drivers of higher sequencing intensity.
Clinical sequencing consumables demand grew 20%, excluding China, for the second consecutive quarter, and management continues to expect most clinical volumes to transition to NovaSeq X by the end of 2026. Over time, the mix shift toward higher-throughput clinical workflows should remain supportive for consumables growth even as research demand stays uneven.
What Ails ILMN?Setbacks in China Market: Illumina continues to face constrained demand in Greater China amid ongoing regulatory and geopolitical uncertainty, keeping the region out of step with the rest of the business. In first-quarter 2026, Greater China revenues were $52 million, down 27.8% year over year. With Illumina still operating under uncertainty tied to its status with Chinese authorities and the resulting friction on commercial activity, visibility on a sustained recovery in China remains limited and can weigh on overall growth and operating leverage.
Macroeconomic Pressures Remain a Concern: Illumina continues to operate in a higher-cost environment shaped by tariffs and supply-chain inflation, which can affect both demand and margins. In the first quarter of 2026, tariffs were a partial offset to underlying cost efficiencies and revenue leverage.
Second-quarter guidance calls for an operating margin of around 22%, reflecting a higher instrument mix, near-term inflationary impacts tied to freight and higher electronic component costs, and incremental costs from a full quarter of SomaLogic. Management expects mitigation actions to offset these cost items over the balance of the year, but ongoing volatility in trade policy and input costs can still create uneven quarterly performance and limit visibility for customers facing tighter budgets.
ILMN Stock Estimate TrendThe Zacks Consensus Estimate for ILMN’s 2026 EPS has increased 0.4% to $5.19 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $4.56 billion. This suggests a 5.1% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 6.2% compared to the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 35.4% against the industry’s 10.6% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 6.3% against the industry’s 9.6% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.8% against the industry’s 10.5% decline over the past year.
For years, progress in quantum computing has been comparable to one of its core principles – quantum superposition – in that it has simultaneously been continuously impressive and failed to produce a decisive breakthrough, all the while defaulting to the latter, somewhat disappointing side whenever scrutinized.
This year, however, appears to finally be promising a major leap forward in the field, judging both by recent milestones with projects like Quantinuum’s (NASDAQ: QNT) Helios and by President Donald Trump announcing $2.013 billion in federal incentives for involved companies earlier in 2026.
Under the circumstances, Finbold decided to examine some of the most promising public quantum computing companies investors might consider trading in the coming months.
IonQ (NYSE: IONQ) IonQ (NYSE: IONQ) is an American quantum computing software and hardware company that has been a major player in its sector for approximately a decade. Additionally, its time in the stock market has, so far, been strong with an all-time rally greater than 300%.
Furthermore, despite not quite maintaining the momentum in 2026, IONQ’s shares have performed relatively close to the benchmark indices and are, at their latest closing price of $49.12, 5.02% in the green year-to-date (YTD).
IonQ stock price YTD chart. Source: Google More importantly, the company boasts substantial analyst confidence. Indeed, IonQ stock is not only rated as a ‘Strong Buy’ overall, but is also expected on average to rise 41.11% to $69.31 in the coming 12 months, per the data Finbold retrieved from TipRanks on July 3.
Wall Street sets IonQ stock price target for the next 12 months. Source: TipRanks D-Wave Quantum (NYSE: QBTS) D-Wave Quantum (NYSE: QBTS) is something of a pioneer in its sector, considering it boasts the claim of being the first firm on the planet to sell computers that exploit quantum effects as part of their operations.
Additionally, the company can brag about a rather impressive list of early clients, including the Los Alamos National Laboratory, the University of Southern California, NASA, Alphabet (NASDAQ: GOOGL), and Lockheed Martin (NYSE: LMT).
Still, QBTS stock’s YTD performance has not been as laudable, as it featured a 19.91% drop to $22.53.
D-Wave Quantum stock price YTD chart. Source: Google Nonetheless, D-Wave shares appear like an enticing investment for 2026 with Wall Street considering the equity a ‘Strong Buy’and anticipating a 69.87% rally to $38.27 in the coming 52 weeks.
Wall Street sets QBTS stock price target for the next 12 months. Source: TipRanks Quantinuum Inc (NASDAQ: QNT) Despite being a relative newcomer, given its initial public offering (IPO) was as recent as June 4, Quantinuum is already proving a highly promising company whose portfolio was recently bolstered by the Helios quantum computer, acclaimed for its balance of scalability and record-breaking accuracy.
The hopes for the company have also, despite its short tenure, been reflected in the stock price, which has risen 32.53% in the last month to its latest – Thursday, July 2 – closing-bell price of $74.56.
Quantinuum stock price all-time chart. Source: Google Looking ahead, institutional investors appear confident in QNT shares’ future, overall rating the equity as a ‘Strong Buy’and foreseeing a 32.44% rise to $98.75.
Wall Street sets QNT stock price target for the next 12 months. Source: TipRanks Still, as with any IPO, it might be worth holding off on investing in Quantinuum until it has been ‘seasoned’ more, due to new stock often enjoying strong early rallies before suffering steep corrections that occasionally leave them below their original prices for years.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Advance Auto Parts (AAP - Free Report) Advance Auto Parts, Inc. operates in the U.S. automotive aftermarket industry and is primarily engaged in selling replacement parts (excluding tires), accessories, batteries and maintenance items for domestic and imported cars, vans, sport utility vehicles, light and heavy-duty trucks. It is a leading automotive parts provider in North America, serving both the do-it-yourself or DIY and professional installers (professional) as well as independently owned operators.
AAP is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Retail-Wholesale stock. AAP has a Momentum Style Score of B, and shares are up 10.1% over the past four weeks.
10 analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.17 to $2.94 per share. AAP also boasts an average earnings surprise of +62.1%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AAP should be on investors' short list.
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium service, which provides daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter, makes these more manageable goals. All of the features can help you identify what stocks to buy, what to sell, and what are today's hottest industries.
Also included in Zacks Premium is the Focus List. This is a long-term portfolio of top stocks that have all the traits to beat the market.
Breaking Down the Zacks Focus ListIf you could get access to a curated list of stocks to kickstart your investment portfolio, wouldn't you jump at the chance to take a peek?
That's what the Zacks Focus List, a portfolio of 50 stocks, offers investors. Not only does it serve as a starting point for long-term investors, but all stocks included in the list are poised to outperform the market over the next 12 months.
What makes the Focus List even more helpful is that each selection is accompanied by a full Zacks Analyst Report, which explains the reasoning behind every stock's selection and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates, or expectations of growth and profitability, come from brokerage analysts who track publicly traded companies; these analysts work together with company management to analyze every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
What a company will earn down the road also needs to be taken into consideration, and this is why earnings estimate revisions are so important.
Stocks that receive upward earnings estimate revisions are more likely to receive even more upward changes in the future. For example, if an analyst raised their estimates last month, they're more likely to do it again this month, and other analysts are likely to do the same.
Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions to make it easier to build a winning portfolio.
There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise. Each one of these features is then given a raw score that's recalculated every night and compiled into the Rank. Using this data, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell."
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
Because stock prices react to revisions, buying stocks with rising earnings estimates can be very profitable. Focus List stocks offer investors a great opportunity to get into companies whose future earnings estimates will be raised, potentially leading to price momentum.
Focus List Spotlight: Virtu Financial (VIRT - Free Report) Headquartered in New York, NY, Virtu Financial is a market-leading financial services firm that leverages cutting-edge technology to provide execution services and data, analytics and connectivity products to its clients and deliver liquidity to the global markets. It provides a wide array of offerings in execution, liquidity sourcing, analytics and broker-neutral, multi-dealer platforms in workflow technology. The company was founded in 2008.
On July 31, 2023, VIRT was added to the Focus List at $18.9 per share. Shares have increased 226.83% to $61.77 since then, and the company is a #1 (Strong Buy) on the Zacks Rank.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.58 to $6.51. VIRT boasts an average earnings surprise of 25.1%.
Moreover, analysts are expecting VIRT's earnings to grow 13.6% for the current fiscal year.
Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
